[Federal Register Volume 64, Number 181 (Monday, September 20, 1999)]
[Notices]
[Pages 50818-50819]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-24366]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Committee on Immunization Practices: Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting:

    Name: Advisory Committee on Immunization Practices (ACIP).
    Times and Dates: 8 a.m.-6 p.m., October 20, 1999; 8 a.m.-6 p.m., 
October 21, 1999; 8 a.m.-12 p.m., October 22, 1999.
    Place: Auditorium B, Centers for Disease Control and Prevention, 
1600 Clifton Road, N.E., Atlanta, Georgia 30333.

[[Page 50819]]

    Status: Open to the public, limited only by the space available.
    Purpose: The Committee is charged with advising the Director, 
CDC, on the appropriate uses of immunizing agents. In addition, 
under 42 U.S.C. 1396s, the Committee is mandated to establish and 
periodically review and, as appropriate, revise the list of vaccines 
for administration to vaccine-eligible children through the Vaccines 
for Children (VFC) program, along with schedules regarding the 
appropriate periodicity, dosage, and contraindications applicable to 
the vaccines.
    Matters To Be Discussed: The agenda will include a review of 
issues relating to the goal of eliminating or reducing the 
thimerosal content of vaccines; adoption of the harmonized 
immunization schedule for the year 2000; recommendations for use of 
meningococcal polysaccharide vaccine for college students; an update 
on the use of meningococcal conjugate vaccine in the United Kingdom; 
recommendations for use of pneumococcal conjugate vaccine; inclusion 
of the pneumococcal vaccine in the Vaccines for Children program; 
recommendations for use of neuraminidase inhibitors; use of 
influenza vaccine in pregnant women and young children; plans to 
revise the adult immunization recommendations; approval of standing 
orders for adult immunization, adolescent/adults acellular pertussis 
products; adverse events reported after use of yellow fever vaccine 
in older adults; prevention of pneumococcal disease in adults <65 
years old; an update on the bioterrorism work group; military 
experience on use of anthrax vaccine; an update from the Food and 
Drug Administration; update from the National Center for Infectious 
Diseases; update from the National Immunization Program; update from 
the Vaccine Injury Compensation Program; update from the National 
Vaccine Program; rotavirus vaccine and intussusception; and 
resumption or continued suspension of use of rotavirus vaccine. 
Other matters of relevance among the committee's objectives may be 
discussed.
    Agenda items are subject to change as priorities dictate.
    Contact Person For More Information: John R. Livengood, M.D., 
Director, Epidemiology and Surveillance Division, National 
Immunization Program, CDC, CDC, 1600 Clifton Road, NE, m/s E61, 
Atlanta, Georgia 30333. Telephone 404/639-8254.
    The Director, Management Analysis and Services office has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.

    Dated: September 14, 1999.
John C. Burckhardt,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 99-24366 Filed 9-17-99; 8:45 am]
BILLING CODE 4163-18-P